Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: A preliminary report
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.111137 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Sisi Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Subcutaneous immunotherapy (SCIT) and dupilumab are important treatments for patients with moderate to severe atopic dermatitis (AD). However, in clinical practice, poor response to allergen immunotherapy (AIT) or dupilumab has been observed in some patients. It is unknown whether combining dupilumab and SCIT can improve treatment responses in patients with moderate to severe AD that is resistant to dupilumab or SCIT monotherapy. This single-centre, retrospective, observational, real-world study evaluated the efficacy and safety of dupilumab and SCIT for refractory moderate to severe AD. The data of ten patients with moderate to severe atopic dermatitis who were treated with dupilumab and SCIT were retrospectively analysed. The scoring atopic dermatitis (SCORAD) score, numerical rating scale (NRS), and atopic dermatitis control test (ADCT) scores and eosinophil and total IgE levels before and after add-on therapy were compared and analysed. The SCORAD, NRS, and ADCT scores decreased significantly at four and 12 weeks after the initiation of add-on therapy and plateaued during maintenance treatment. The eosinophil and total IgE levels were not significantly different before and after add-on therapy. No serious adverse reactions were reported in any patient during add-on therapy. This study indicates that the combination of dupilumab and SCIT safely improves the treatment response of patients with moderate to severe AD who are resistant to dupilumab or SCIT monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China.
- School of Medicine, Chongqing University, Chongqing 400038, China.
- Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China. Electronic address: drsongzq@hotmail.com.
- Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China. Electronic address: chenqq0548@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Deng, S., Wang, H., Chen, S., Kong, M., Yang, X., Song, Z., & Chen, Q. (2023). Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: A preliminary report. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.111137
Vancouver
Deng S, Wang H, Chen S, Kong M, Yang X, Song Z, et al. Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: A preliminary report. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.111137
BibTeX
@article{Deng2023,
author = {Deng, Sisi and Wang, Huan and Chen, Shuguang and Kong, Minmin and Yang, Xianjie and Song, Zhiqiang and Chen, Qiquan},
title = {Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: A preliminary report},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.111137}
}
EUVIMED